National Asset Management, Inc. Otonomy, Inc. Transaction History

National Asset Management, Inc.

  • $3.82 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 21, 2023
BUY
$0.07 - $0.23 $700 - $2,300
10,000 New
10,000 $0

About OTONOMY, INC.

OTIC Quotes by TradingView
  • Ticker OTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,990,400
  • Description
  • Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...
More about OTIC
Track This Portfolio

Track National Asset Management, Inc. Portfolio

Follow National Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on National Asset Management, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email